Published in Nature on August 04, 2010
Novel classes of antibiotics or more of the same? Br J Pharmacol (2011) 2.99
All tangled up: how cells direct, manage and exploit topoisomerase function. Nat Rev Mol Cell Biol (2011) 2.66
Drugging topoisomerases: lessons and challenges. ACS Chem Biol (2013) 2.46
The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage. J Mol Biol (2012) 1.87
Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. Appl Microbiol Biotechnol (2011) 1.85
Interfacial inhibitors: targeting macromolecular complexes. Nat Rev Drug Discov (2011) 1.80
The challenge of developing robust drugs to overcome resistance. Drug Discov Today (2011) 1.43
Mechanism of quinolone action and resistance. Biochemistry (2014) 1.34
Structure of a topoisomerase II-DNA-nucleotide complex reveals a new control mechanism for ATPase activity. Nat Struct Mol Biol (2012) 1.09
Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding. J Biol Chem (2014) 1.08
Architecture and conservation of the bacterial DNA replication machinery, an underexploited drug target. Curr Drug Targets (2012) 1.07
Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance. Nucleic Acids Res (2013) 1.04
Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent. J Clin Microbiol (2014) 1.01
Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance. Biochemistry (2011) 1.01
In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens. Antimicrob Agents Chemother (2016) 1.01
DNA cleavage and opening reactions of human topoisomerase IIα are regulated via Mg2+-mediated dynamic bending of gate-DNA. Proc Natl Acad Sci U S A (2012) 0.99
NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy. Antimicrob Agents Chemother (2014) 0.99
Molecular basis of antibiotic multiresistance transfer in Staphylococcus aureus. Proc Natl Acad Sci U S A (2013) 0.98
The role of DNA bending in type IIA topoisomerase function. Nucleic Acids Res (2013) 0.98
Impact of the E540V amino acid substitution in GyrB of Mycobacterium tuberculosis on quinolone resistance. Antimicrob Agents Chemother (2011) 0.98
Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis. Antimicrob Agents Chemother (2011) 0.97
ATP binding controls distinct structural transitions of Escherichia coli DNA gyrase in complex with DNA. Nat Struct Mol Biol (2012) 0.97
Pharmacodynamic Profile of GSK2140944 against Methicillin-Resistant Staphylococcus aureus in a Murine Lung Infection Model. Antimicrob Agents Chemother (2015) 0.95
Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2016) 0.94
Oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad spectrum antibacterial agents. ACS Med Chem Lett (2014) 0.94
The antibacterial lead discovery challenge. Nat Rev Drug Discov (2010) 0.91
Target-based resistance in Pseudomonas aeruginosa and Escherichia coli to NBTI 5463, a novel bacterial type II topoisomerase inhibitor. Antimicrob Agents Chemother (2014) 0.89
Local sensing of global DNA topology: from crossover geometry to type II topoisomerase processivity. Nucleic Acids Res (2011) 0.87
Insights into the mechanism of inhibition of novel bacterial topoisomerase inhibitors from characterization of resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother (2015) 0.87
Multicenter Investigation of Gepotidacin (GSK2140944) Agar Dilution Quality Control Determinations for Neisseria gonorrhoeae ATCC 49226. Antimicrob Agents Chemother (2016) 0.87
Structure of an 'open' clamp type II topoisomerase-DNA complex provides a mechanism for DNA capture and transport. Nucleic Acids Res (2013) 0.87
Structural insight into negative DNA supercoiling by DNA gyrase, a bacterial type 2A DNA topoisomerase. Nucleic Acids Res (2013) 0.87
Physicochemical Properties of Ion Pairs of Biological Macromolecules. Biomolecules (2015) 0.87
Time for a change: addressing R&D and commercialization challenges for antibacterials. Philos Trans R Soc Lond B Biol Sci (2015) 0.86
Use of divalent metal ions in the DNA cleavage reaction of topoisomerase IV. Nucleic Acids Res (2011) 0.86
Role of the water-metal ion bridge in mediating interactions between quinolones and Escherichia coli topoisomerase IV. Biochemistry (2014) 0.85
Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin. Nat Commun (2015) 0.84
Whole-genome sequencing targets drug-resistant bacterial infections. Hum Genomics (2015) 0.84
Application of a novel microtitre plate-based assay for the discovery of new inhibitors of DNA gyrase and DNA topoisomerase VI. PLoS One (2013) 0.83
Distinct regions of the Escherichia coli ParC C-terminal domain are required for substrate discrimination by topoisomerase IV. J Mol Biol (2013) 0.83
Bypassing fluoroquinolone resistance with quinazolinediones: studies of drug-gyrase-DNA complexes having implications for drug design. ACS Chem Biol (2014) 0.83
Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones. Clin Ophthalmol (2013) 0.83
Characterization of flavonol inhibition of DnaB helicase: real-time monitoring, structural modeling, and proposed mechanism. J Biomed Biotechnol (2012) 0.83
Functional determinants of gate-DNA selection and cleavage by bacterial type II topoisomerases. Nucleic Acids Res (2013) 0.82
A new crystal structure of the bifunctional antibiotic simocyclinone D8 bound to DNA gyrase gives fresh insight into the mechanism of inhibition. J Mol Biol (2014) 0.82
Piperonal ciprofloxacin hydrazone induces growth arrest and apoptosis of human hepatocarcinoma SMMC-7721 cells. Acta Pharmacol Sin (2012) 0.82
Topoisomerase II minimizes DNA entanglements by proofreading DNA topology after DNA strand passage. Nucleic Acids Res (2013) 0.81
Benzimidazoles: novel mycobacterial gyrase inhibitors from scaffold morphing. ACS Med Chem Lett (2014) 0.81
How the ESRF helps industry and how they help the ESRF. Acta Crystallogr D Biol Crystallogr (2013) 0.81
Molecular basis for the differential quinolone susceptibility of mycobacterial DNA gyrase. Antimicrob Agents Chemother (2014) 0.81
Exploring the mode of action of bioactive compounds by microfluidic transcriptional profiling in mycobacteria. PLoS One (2013) 0.80
Topoisomerase II from Human Malaria Parasites: EXPRESSION, PURIFICATION, AND SELECTIVE INHIBITION. J Biol Chem (2015) 0.80
Evaluating the genotoxicity of topoisomerase-targeted antibiotics. Mutagenesis (2011) 0.80
Improvement of the pharmacokinetics and in vivo antibacterial efficacy of a novel type IIa topoisomerase inhibitor by formulation in liposomes. Antimicrob Agents Chemother (2013) 0.80
Crystallization and initial crystallographic analysis of covalent DNA-cleavage complexes of Staphyloccocus aureus DNA gyrase with QPT-1, moxifloxacin and etoposide. Acta Crystallogr F Struct Biol Commun (2015) 0.79
Gepotidacin (GSK2140944) In Vitro Activity against Gram-positive and Gram-negative Bacteria (MBC/MIC, Kill Kinetics, Checkerboard, PAE/SME tests). Antimicrob Agents Chemother (2017) 0.79
Structural Dynamics and Mechanochemical Coupling in DNA Gyrase. J Mol Biol (2016) 0.78
Left-Hand Side Exploration of Novel Bacterial Topoisomerase Inhibitors to Improve Selectivity against hERG Binding. ACS Med Chem Lett (2015) 0.78
Gyramides prevent bacterial growth by inhibiting DNA gyrase and altering chromosome topology. ACS Chem Biol (2014) 0.78
Structure based in silico analysis of quinolone resistance in clinical isolates of Salmonella Typhi from India. PLoS One (2015) 0.78
Functional Analyses of the Toxoplasma gondii DNA Gyrase Holoenzyme: A Janus Topoisomerase with Supercoiling and Decatenation Abilities. Sci Rep (2015) 0.78
Microspectrometric insights on the uptake of antibiotics at the single bacterial cell level. Sci Rep (2015) 0.77
antibacTR: dynamic antibacterial-drug-target ranking integrating comparative genomics, structural analysis and experimental annotation. BMC Genomics (2014) 0.77
Induction of mycobacterial resistance to quinolone class antimicrobials. Antimicrob Agents Chemother (2012) 0.77
The impact of the C-terminal domain on the interaction of human DNA topoisomerase II α and β with DNA. PLoS One (2011) 0.77
In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus. Antimicrob Agents Chemother (2016) 0.76
Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs. Antimicrob Agents Chemother (2015) 0.76
Deoxynybomycins inhibit mutant DNA gyrase and rescue mice infected with fluoroquinolone-resistant bacteria. Nat Commun (2015) 0.76
Direct control of type IIA topoisomerase activity by a chromosomally encoded regulatory protein. Genes Dev (2014) 0.76
Structure of a quinolone-stabilized cleavage complex of topoisomerase IV from Klebsiella pneumoniae and comparison with a related Streptococcus pneumoniae complex. Acta Crystallogr D Struct Biol (2016) 0.76
Mycobacterium fluoroquinolone resistance protein B, a novel small GTPase, is involved in the regulation of DNA gyrase and drug resistance. Nucleic Acids Res (2012) 0.76
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus. J Med Chem (2014) 0.76
DNA replication proteins as potential targets for antimicrobials in drug-resistant bacterial pathogens. J Antimicrob Chemother (2017) 0.75
In Vitro and In Vivo Characterization of the Novel Oxabicyclooctane-Linked Bacterial Topoisomerase Inhibitor AM-8722, a Selective, Potent Inhibitor of Bacterial DNA Gyrase. Antimicrob Agents Chemother (2016) 0.75
Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin Against Gram-Positive Organisms Using Data From Murine Infection Models. Antimicrob Agents Chemother (2016) 0.75
Beating bad bugs. Nat Rev Drug Discov (2010) 0.75
Recent Advances in the Rational Design and Optimization of Antibacterial Agents. Medchemcomm (2016) 0.75
Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria. Antimicrob Agents Chemother (2017) 0.75
Synthesis and evaluation of 1-cyclopropyl-2-thioalkyl-8-methoxy fluoroquinolones. Bioorg Med Chem Lett (2011) 0.75
Gepotidacin (GSK2140944) In Vitro Activity against Neisseria gonorrhoeae (MIC/MBC, Kill Kinetics, Checkerboard, PAE/SME tests). Antimicrob Agents Chemother (2017) 0.75
Novobiocin Susceptibility of MukBEF-Deficient Escherichia coli Is Combinatorial with Efflux and Resides in DNA Topoisomerases. Antimicrob Agents Chemother (2016) 0.75
Understanding the structural mechanisms of antibiotic resistance sets the platform for new discovery. Future Microbiol (2015) 0.75
Structure-activity studies of divin: an inhibitor of bacterial cell division. ACS Med Chem Lett (2013) 0.75
Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones. Nucleic Acids Res (2016) 0.75
Trimethoxy-benzaldehyde levofloxacin hydrazone inducing the growth arrest and apoptosis of human hepatocarcinoma cells. Cancer Cell Int (2013) 0.75
Exploring the active site of the Streptococcus pneumoniae topoisomerase IV-DNA cleavage complex with novel 7,8-bridged fluoroquinolones. Open Biol (2016) 0.75
DNA gyrase with a single catalytic tyrosine can catalyze DNA supercoiling by a nicking-closing mechanism. Nucleic Acids Res (2016) 0.75
A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone. Curr Med Chem (2016) 0.75
Antibacterial small molecules targeting the conserved TOPRIM domain of DNA gyrase. PLoS One (2017) 0.75
Structure elucidation and in silico docking studies of a novel furopyrimidine antibiotics synthesized by endolithic bacterium Actinomadura sp. AL2. World J Microbiol Biotechnol (2017) 0.75
Interactions between quinolones and Bacillus anthracis gyrase and the basis of drug resistance. Biochemistry (2017) 0.75
In Vitro Activities of Gepotidacin (GSK2140944) and Other Antimicrobial Agents Against Human Mycoplasmas and Ureaplasmas. Antimicrob Agents Chemother (2017) 0.75
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr (1994) 187.88
Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr (1998) 169.28
Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr (1997) 137.43
PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr (2002) 53.61
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis (2009) 22.98
Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov (2006) 15.21
Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis (2005) 8.77
Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer (2009) 5.06
Mapping the active site tyrosine of Escherichia coli DNA gyrase. J Biol Chem (1987) 4.68
Structure and mechanism of DNA topoisomerase II. Nature (1996) 4.56
DNA gyrase: purification and catalytic properties of a fragment of gyrase B protein. Proc Natl Acad Sci U S A (1979) 4.34
A robust and scalable microfluidic metering method that allows protein crystal growth by free interface diffusion. Proc Natl Acad Sci U S A (2002) 4.16
Crystal structure of the breakage-reunion domain of DNA gyrase. Nature (1997) 4.10
Crystal structure of an N-terminal fragment of the DNA gyrase B protein. Nature (1991) 3.93
DNA topoisomerases: harnessing and constraining energy to govern chromosome topology. Q Rev Biophys (2008) 3.50
Toprim--a conserved catalytic domain in type IA and II topoisomerases, DnaG-type primases, OLD family nucleases and RecR proteins. Nucleic Acids Res (1998) 2.82
Structural basis for gate-DNA recognition and bending by type IIA topoisomerases. Nature (2007) 2.79
Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents. Chem Rev (2005) 2.70
Where freedom is given, liberties are taken. Structure (1995) 2.59
Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat Struct Mol Biol (2009) 2.05
Multiple modes of Escherichia coli DNA gyrase activity revealed by force and torque. Nat Struct Mol Biol (2007) 1.91
Mechanism of quinolone resistance in Staphylococcus aureus. J Infect Chemother (2000) 1.88
A novel and unified two-metal mechanism for DNA cleavage by type II and IA topoisomerases. Nature (2010) 1.59
Crystal structure of a complex of a type IA DNA topoisomerase with a single-stranded DNA molecule. Nature (2001) 1.54
The role of GyrB in the DNA cleavage-religation reaction of DNA gyrase: a proposed two metal-ion mechanism. J Mol Biol (2002) 1.48
Structural similarities between topoisomerases that cleave one or both DNA strands. Proc Natl Acad Sci U S A (1998) 1.47
Probing the limits of the DNA breakage-reunion domain of the Escherichia coli DNA gyrase A protein. J Biol Chem (1991) 1.36
Identification of active site residues in the "GyrA" half of yeast DNA topoisomerase II. J Biol Chem (1998) 1.32
Effects of magnesium and related divalent metal ions in topoisomerase structure and function. Nucleic Acids Res (2009) 1.32
DNA cleavage is not required for the binding of quinolone drugs to the DNA gyrase-DNA complex. Biochemistry (1996) 1.31
Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases. Antimicrob Agents Chemother (2008) 1.25
Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV. Antimicrob Agents Chemother (2009) 1.24
A crystal structure of the bifunctional antibiotic simocyclinone D8, bound to DNA gyrase. Science (2009) 1.23
Similarity in the catalysis of DNA breakage and rejoining by type IA and IIA DNA topoisomerases. Proc Natl Acad Sci U S A (1999) 1.20
Human topoisomerase IIalpha uses a two-metal-ion mechanism for DNA cleavage. Nucleic Acids Res (2008) 1.17
A "moving metal mechanism" for substrate cleavage by the DNA repair endonuclease APE-1. Proteins (2007) 1.16
Structural studies of E. coli topoisomerase III-DNA complexes reveal a novel type IA topoisomerase-DNA conformational intermediate. J Mol Biol (2007) 1.11
Crystal structure of DNA gyrase B' domain sheds lights on the mechanism for T-segment navigation. Nucleic Acids Res (2009) 1.03
Crystal structure of the DNA gyrase GyrA N-terminal domain from Mycobacterium tuberculosis. Proteins (2010) 1.03
Coupling between ATP binding and DNA cleavage by DNA topoisomerase II: A unifying kinetic and structural mechanism. J Biol Chem (2008) 1.02
In the presence of subunit A inhibitors DNA gyrase cleaves DNA fragments as short as 20 bp at specific sites. Nucleic Acids Res (1997) 0.98
A GyrB-GyrA fusion protein expressed in yeast cells is able to remove DNA supercoils but cannot substitute eukaryotic topoisomerase II. Genes Cells (2002) 0.94
A ParE-ParC fusion protein is a functional topoisomerase. Biochemistry (2001) 0.94
Novel pyrazole derivatives as potent inhibitors of type II topoisomerases. Part 1: synthesis and preliminary SAR analysis. Bioorg Med Chem Lett (2007) 0.92
Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains. Bioorg Med Chem Lett (2007) 0.92
Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov (2006) 15.21
Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth. Vital Health Stat 23 (2005) 8.99
Sexual behavior and selected health measures: men and women 15-44 years of age, United States, 2002. Adv Data (2005) 5.62
Alzheimer's disease. Lancet (2011) 5.35
Use of contraception in the United States: 1982-2008. Vital Health Stat 23 (2010) 4.70
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res (2006) 4.20
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature (2012) 4.08
Current contraceptive use in the United States, 2006-2010, and changes in patterns of use since 1995. Natl Health Stat Report (2012) 3.28
Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat Cell Biol (2006) 3.16
The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol (2010) 3.15
Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol (2010) 2.72
Intended and unintended births in the United States: 1982-2010. Natl Health Stat Report (2012) 2.52
Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A (2002) 2.45
Crystal structure of human cytochrome P450 2D6. J Biol Chem (2005) 2.34
ERK activation drives intestinal tumorigenesis in Apc(min/+) mice. Nat Med (2010) 2.09
Fertility, contraception, and fatherhood: data on men and women from cycle 6 (2002) of the 2002 National Survey of Family Growth. Vital Health Stat 23 (2006) 1.97
Human cancer cells express Slug-based epithelial-mesenchymal transition gene expression signature obtained in vivo. BMC Cancer (2011) 1.89
Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol (2002) 1.88
Laparoscopic nephrectomy in xanthogranulomatous pyelonephritis: 7-year single-surgeon outcome. Urology (2011) 1.82
A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Res (2008) 1.80
T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion. Cancer Res (2012) 1.74
Current contraceptive status among women aged 15-44: United States, 2011-2013. NCHS Data Brief (2014) 1.70
Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J Immunol Methods (2008) 1.62
Human epidermal growth factor receptor signaling contributes to tumor growth via angiogenesis in her2/neu-expressing experimental Wilms' tumor. J Pediatr Surg (2003) 1.59
Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc Natl Acad Sci U S A (2006) 1.59
Immunodominance of an antiviral cytotoxic T cell response is shaped by the kinetics of viral protein expression. J Immunol (2003) 1.52
Measuring strategic control in artificial grammar learning. Conscious Cogn (2011) 1.50
Genomic approaches to antibacterial discovery. Methods Mol Biol (2004) 1.46
Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol (2010) 1.45
Current Contraceptive Use and Variation by Selected Characteristics Among Women Aged 15-44: United States, 2011-2013. Natl Health Stat Report (2015) 1.44
Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov (2012) 1.42
Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against gram-positive pathogens. J Med Chem (2002) 1.42
Quality of red blood cells using autotransfusion devices: a comparative analysis. J Extra Corpor Technol (2003) 1.42
A distinct chemokine axis does not account for enrichment of Foxp3(+) CD4(+) T cells in carcinogen-induced fibrosarcomas. Immunology (2015) 1.40
Conventional dendritic cells regulate the outcome of colonic inflammation independently of T cells. Proc Natl Acad Sci U S A (2007) 1.35
Suppression of tumour-specific CD4⁺ T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut (2011) 1.33
Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat Biotechnol (2004) 1.26
Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation. Mol Cancer Res (2008) 1.25
Novel chromosomally encoded multidrug efflux transporter MdeA in Staphylococcus aureus. Antimicrob Agents Chemother (2004) 1.21
Optimised anaesthesia to reduce post operative cognitive decline (POCD) in older patients undergoing elective surgery, a randomised controlled trial. PLoS One (2012) 1.21
Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Res (2010) 1.21
Comparative genomics of Klebsiella pneumoniae strains with different antibiotic resistance profiles. Antimicrob Agents Chemother (2011) 1.20
Orexin-1 receptor signalling within the ventral tegmental area, but not the paraventricular thalamus, is critical to regulating cue-induced reinstatement of cocaine-seeking. Int J Neuropsychopharmacol (2011) 1.17
Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol (2011) 1.17
Trends in long-acting reversible contraception use among U.S. women aged 15-44. NCHS Data Brief (2015) 1.17
Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureus. Antimicrob Agents Chemother (2002) 1.17
Effects of high-dose B vitamin complex with vitamin C and minerals on subjective mood and performance in healthy males. Psychopharmacology (Berl) (2010) 1.16
Scaffold: a novel carrier for cell and drug delivery. Crit Rev Ther Drug Carrier Syst (2012) 1.15
Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus. Antimicrob Agents Chemother (2008) 1.15
Enterococcus faecalis acetoacetyl-coenzyme A thiolase/3-hydroxy-3-methylglutaryl-coenzyme A reductase, a dual-function protein of isopentenyl diphosphate biosynthesis. J Bacteriol (2002) 1.09
The generation of CD25+ CD4+ regulatory T cells that prevent allograft rejection does not compromise immunity to a viral pathogen. J Immunol (2005) 1.09
The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients. Cancer Chemother Pharmacol (2011) 1.07
Honey dressing versus silver sulfadiazene dressing for wound healing in burn patients: a retrospective study. J Cutan Aesthet Surg (2011) 1.06
Molecular evolution perspectives on intraspecific lateral DNA transfer of topoisomerase and gyrase loci in Streptococcus pneumoniae, with implications for fluoroquinolone resistance development and spread. Antimicrob Agents Chemother (2005) 1.06
Identification of a novel polymorphism in the 3'UTR of the L-arginine transporter gene SLC7A1: contribution to hypertension and endothelial dysfunction. Circulation (2007) 1.05
Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy. Ultrasound Med Biol (2012) 1.05
Cocaine- and amphetamine-regulated transcript (CART) signaling within the paraventricular thalamus modulates cocaine-seeking behaviour. PLoS One (2010) 1.05
The effect of triton concentration on the activity of undecaprenyl pyrophosphate synthase inhibitors. J Biomol Screen (2003) 1.03
Toll-like receptor signaling in intestinal epithelial cells contributes to colonic homoeostasis. Curr Opin Gastroenterol (2007) 1.03
Structural analysis of an eIF3 subcomplex reveals conserved interactions required for a stable and proper translation pre-initiation complex assembly. Nucleic Acids Res (2011) 1.03
Molecular complexity and fragment-based drug discovery: ten years on. Curr Opin Chem Biol (2011) 1.03
Quality of red blood cells using the Dideco Electa autotransfusion device. J Extra Corpor Technol (2005) 1.00
Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma. Int J Oncol (2009) 0.99
Home sweet home: the tumor microenvironment as a haven for regulatory T cells. Front Immunol (2013) 0.99
Staphylococcus aureus 3-hydroxy-3-methylglutaryl-CoA synthase: crystal structure and mechanism. J Biol Chem (2004) 0.98
Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. Eur J Immunol (2013) 0.96
Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease. Dement Geriatr Cogn Disord (2008) 0.96
Regulatory T cells inhibit Fas ligand-induced innate and adaptive tumour immunity. Eur J Immunol (2007) 0.96
Acute fulminant necrotizing amoebic colitis: a rare and fatal complication of amoebiasis: a case report. Cases J (2009) 0.95
Novel hydroxyl tricyclics (e.g., GSK966587) as potent inhibitors of bacterial type IIA topoisomerases. Bioorg Med Chem Lett (2013) 0.95
Structural variation and inhibitor binding in polypeptide deformylase from four different bacterial species. Protein Sci (2003) 0.95
Staphylococcus aureus gyrase-quinolone-DNA ternary complexes fail to arrest replication fork progression in vitro. Effects of salt on the DNA binding mode and the catalytic activity of S. aureus gyrase. J Biol Chem (2002) 0.94
Carcinoma colon presenting as cutaneous metastasis to an old operative scar of hysterectomy. J Cancer Res Ther (2010) 0.94
A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma. Clin Cancer Res (2011) 0.93
Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4+ T-cell immunity. Eur J Immunol (2012) 0.92
Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature. Int J Oncol (2004) 0.92
The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol (2010) 0.92
Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients. Br J Clin Pharmacol (2012) 0.91
Effects of a multi-vitamin/mineral supplement on cognitive function and fatigue during extended multi-tasking. Hum Psychopharmacol (2010) 0.91
Fragment screening: an introduction. Mol Biosyst (2006) 0.91
Over expression of wild type or a catalytically dead mutant of Sirtuin 6 does not influence NFκB responses. PLoS One (2012) 0.90
Reassurance through surveillance in the face of clinical uncertainty: the experience of women at risk of familial breast cancer. Health Expect (2000) 0.90
Multiple proviral integration events after virological synapse-mediated HIV-1 spread. Virology (2013) 0.89
Biomolecular markers and involution of hemangiomas. J Pediatr Surg (2004) 0.89
Dermatan carriers for neovascular transport targeting, deep tumor penetration and improved therapy. J Control Release (2005) 0.89
Predictors of survival in a Huntington's disease population from southern Italy. Can J Neurol Sci (2012) 0.89
Opposing roles of RAGE and Myd88 signaling in extensive liver resection. FASEB J (2011) 0.89
Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling. Cancer Res (2006) 0.88
Fas ligand breaks tolerance to self-antigens and induces tumor immunity mediated by antibodies. Cancer Cell (2002) 0.88